Last reviewed · How we verify
NCT03206450
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
trial testing Biospecimen Collection in Osteosarcoma in 224 participants. Completed in 30 June 2024.
30 June 2023
Quick facts
| Lead sponsor | Children's Oncology Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 224 |
| Start date | 6 December 2017 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 99 locations across Canada, United States, Puerto Rico |
Drugs / interventions tested
- Biospecimen Collection — full drug profile →
- Laboratory Biomarker Analysis — full drug profile →
- Questionnaire Administration
Conditions studied
- Osteosarcoma — all drugs for Osteosarcoma →
Sponsor
Children's Oncology Group — full company profile →
Who can join
Adults 18 to 50, male only, with Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research trial studies saliva, semen, and blood samples to determine effects of chemotherapy on fertility in osteosarcoma survivors. Study biospecimen samples from osteosarcoma survivors in the laboratory may help doctors learn whether chemotherapy causes fertility problems and to learn more about the long term effects.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research.
Chow EJ, Winestone LE, Lupo PJ, Diller LR, et al · · 2022 · cited 4× · PMID 35732489 · DOI 10.1158/1055-9965.epi-22-0125
Verify or expand the search:
- PubMed search for NCT03206450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biospecimen Collection
Trials testing the same drug.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Osteosarcoma
Currently open trials in the same condition.
- NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
- NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
- NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting
- NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
- NCT06541262 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
Other Children's Oncology Group trials
Trials by the same sponsor.
- NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
- NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
- NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03206450 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
- Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03206450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing